GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » ROE % Adjusted to Book Value

Broncus Holding (HKSE:02216) ROE % Adjusted to Book Value : -38.09% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding ROE % Adjusted to Book Value?

Broncus Holding's ROE % for the quarter that ended in Jun. 2024 was -8.76%. Broncus Holding's PB Ratio for the quarter that ended in Jun. 2024 was 0.23. Broncus Holding's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -38.09%.

Broncus Holding ROE % Adjusted to Book Value Historical Data

The historical data trend for Broncus Holding's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding ROE % Adjusted to Book Value Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -167.92 -18.34 -52.26 -35.83

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -16.21 -36.90 -51.63 -38.09 -35.29

Competitive Comparison of Broncus Holding's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Broncus Holding's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Broncus Holding's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Broncus Holding's ROE % Adjusted to Book Value falls into.


;
;

Broncus Holding ROE % Adjusted to Book Value Calculation

Broncus Holding's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-14.11% / 0.27
=-52.26%

Broncus Holding's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.76% / 0.23
=-38.09%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Broncus Holding ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Broncus Holding's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Broncus Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
HKSE:06118 HKSE:01612 HKSE:02393 HKSE:02297 HKSE:02407 HKSE:02170 HKSE:02500 HKSE:06609 HKSE:06922 HKSE:09877 ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Website
https://www.broncus.com
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Executives
Xu Hong 2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qm12 Limited 2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited 2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines